Early Findings of Cobolimab in Advanced Melanoma Warrant Further Investigation

Source: Targeted Oncology, July 2022

In an interview with Targeted Oncology, Gerald Falchook, MD, discusses the efficacy and safety of cobolimab with or without nivolumab and dostarlimab, as evaluated in the phase 1 AMBER trial.

Preliminary antitumor activity and tolerability has been shown with cobolimab as a monotherapy and in combination with nivolumab (Opdivo) and dostarlimab (Jemperli) in patients with advanced or metastatic melanoma, according to findings from the phase 1 AMBER trial (NCT02817633).

Within the multi-center, open-label, cobolimab was examined in 3 parts. Part 1A examined cobolimab given intravenously (IV) as a monotherapy at 7 doses. In part 1B, cobolimab 1 mg/kg was given in addition to nivolumab 3 mg/kg IV. Finally, part 1C evaluated cobolimab at a dose of 100, 300, or 900 mg plus dostarlimab 500 mg IV.